Thetis Pharmaceuticals Preclinical Data Shows Efficacy of TP-317 in Ulcerative Colitis and Crohn’s Disease Models with Unique Mucosal Healing Mechanism of Action

TP-317 represents a novel approach to treating inflammatory bowel disease (IBD) based on activating intrinsic resolution and repair pathways without compromising immune function

BRANFORD, CT – (May 18, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company with platform technology developing a new class of Resolvin-based therapies for gastrointestinal inflammatory diseases, today announced preclinical data supporting the potential of its lead candidate, TP-317, in inflammatory bowel disease (IBD). TP-317, a patent-protected molecule that delivers Resolvin E1 (RvE1), is being developed as a potential first-in-class, safe, oral agent for treatment of ulcerative colitis and Crohn’s disease.

The data show that once-a-day, oral TP-317 administration reduced symptomatic and histopathological disease activity in the DSS colitis and TNFΔARE models of IBD with superior effects on mucosal tissue regeneration compared to other approved and investigational agents. In addition, TP-317 reduced the expression of key cytokines and enhanced the expression of genes associated with tissue repair in primary colonic tissue explants from ulcerative colitis patients.

“As a first-in-class Resolvin-based oral therapy, TP-317 offers a new approach for treating IBD that has prospects to promote inflammation resolution, mucosal healing and tissue repair without compromising immune function,” stated Dr. Frank Sciavolino, Co-Founder and Chief Scientific Officer of Thetis Pharmaceuticals. “Based on its mechanism of action and anticipated profile as a safe, oral drug, TP-317 offers attractive therapeutic prospects for IBD patients failing 5-ASA, an unaddressed segment with limited therapeutic options beyond escalating to biologics and other immunosuppressive agents that have risk of significant side effects and in many cases black box warnings. We are excited by these results and look forward to initiating clinical trials in 2020.”

Dr. Brian Harvey, Senior Medical Lead at Thetis, will be presenting these data at Digestive Disease Week this Sunday, May 19. Details for the presentation are included below.
Presentation Time: 12:00 PM – 2:00 PM, Sunday, May 19, 2019
Presentation Location: Hall E
Presentation Number: Su1801
• The poster presentation can be found online here

About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company with platform technology developing novel Resolvin-based therapies for the treatment of IBD and other inflammatory diseases. Thetis’ proprietary HEALER platform enables the pharmaceutical development of Resolvins, a unique class of molecules with the potential to transform the treatment of chronic inflammatory diseases. Thetis’ lead candidate, TP-317, is a new molecule that delivers RvE1, an endogenous lipid mediator that resolves inflammation and promotes mucosal tissue repair. TP-317 is being developed as a safe, oral therapy for treating of ulcerative colitis and Crohn’s disease. Beyond IBD, Thetis is developing TP-317 for treatment of eosinophilic esophagitis.

For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) and follow Thetis on Twitter (@thetispharma).

Contact Information
Aaron Mathias
Director of Business Development
amathias@thetispharma.com